Potential prognostic marker for kidney cancer
A recent study to be published in Clinical and Experimental [...]
Liquid biopsies in the era of immuno-oncology
This review, published in the Annals of Oncology, discusses the [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis
Results from the ADAPTeR study to evaluate the role of [...]
Immune checkpoint inhibitors are more effective in PD-L1 positive patients
Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are [...]
The role of biomarkers in predicting response to treatment in metastatic kidney cancer
This review published in Clinical Genitourinary Cancer summarises the current [...]
PD-1 and CTLA-4 as biomarkers for survival in kidney cancer
A recent study published in Journal of Clinical Medicine last [...]
Genetic mutations associated with survival in immunotherapy-treated kidney cancer patients
A recent study of patients with solid tumours treated with [...]
ASCO 2019: Human endogenous retrovirus and efficacy of checkpoint inhibitors in kidney cancer
This paper was presented at the American Society of Clinical [...]
ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
